Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
151.00
-1.00 (-0.66%)
Mar 13, 2026, 1:30 PM CST
Market Cap25.29B -39.1%
Revenue (ttm)35.83M -8.5%
Net Income-340.54M
EPS-2.05
Shares Out167.49M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume117,366
Average Volume253,023
Open150.00
Previous Close152.00
Day's Range149.50 - 153.00
52-Week Range122.00 - 329.50
Beta0.02
RSI33.14
Earnings DateMay 11, 2026

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that is in Phase Ib/II clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and CS028, which is ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 43
Stock Exchange Taipei Exchange
Ticker Symbol 6535
Full Company Profile

Financial Performance

In 2025, Lumosa Therapeutics's revenue was 35.83 million, a decrease of -8.49% compared to the previous year's 39.15 million. Losses were -340.54 million, -19.83% less than in 2024.

Financial Statements